Alkermes plc

NASDAQ:ALKS

Biotechnology

Healthcare
$46.85 +1.77%

+$0.79 today

Market cap
$7.87B
Beta
0.33
P/E (TTM)
49.1
EPS (TTM)
$0.92
52W Low $25.17High $45.76

Volume 1.39M

Average 2.33M

ALKS Debt Repayment

Cash used to repay borrowings during the period.

Alkermes plcNASDAQ: ALKS

Debt Repayment · Q3 FY2026 · quarter ended Sep 2026

Debt repayment outflow grows to $0

Q3 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $3.01B.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, down 18.7 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $753.38M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMSep 2026
$3.01B+1140.8% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Debt Repayment vs competitors

How ALKS compares with its peers on the latest reported figures

  • ALKS's LTM Sep 2026 debt repayment of $3.01B is the largest of the 7 companies compared; the peer median is $1.18M.
  • Its year-over-year change of +1140.8% is the highest of 4, against a peer median of +30.1%.
  • Debt repayment amounts to 171.8% of revenue for ALKS, versus a peer median of 0.2%.
ALKS Competitors Peer median
Debt Repayment for ALKS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALKSAlkermes plcLTM Sep 2026$3.01B +1140.8%—171.8%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$1.02B +30.1%+10.3%21.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$3.09M -57.0%—0.4%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$2.36M +318.1%—1.1%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$0 ——0.0%
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$0 ——0.0%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding ALKS) $1.18M+30.1%+10.3%0.2%

Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.17M)(158.27M)355.76M367.07M241.66M
Depreciation & Amortization78.65M77.86M74.93M28.53M27.17M
Deferred Income Tax5.08M(32.8M)(99.9M)40.52M28.77M
Stock-Based Compensation87.62M94.25M100.91M96.64M98.72M
Change in Working Capital(25.55M)12.71M(36.66M)(98.15M)119.12M
Accounts Receivables(38.01M)25.25M(44.51M)(56.34M)55.49M
Inventory(24.77M)(31.02M)(2.71M)3.09M(14.06M)
Accounts Payables43.31M15.53M23.01M(57.97M)100.89M
Other Working Capital(6.08M)2.95M(12.45M)13.06M(23.2M)
Other Non-Cash Items4.08M27.28M6.33M4.51M5.31M
Operating Cash Flow101.72M21.04M401.35M439.12M520.75M
Capital Expenditures(29.02M)(38.26M)(48.05M)(33.48M)(40.42M)
Acquisitions (Net)(713K)485K097.98M2.79M
Purchases of Investments(340.42M)(309.67M)(254.47M)(486.55M)(364.37M)
Sales of Investments295.01M281.63M355.52M310.29M697.49M
Other Investing Activities8.94M1.27M354K461K0
Investing Cash Flow(66.2M)(64.54M)53.36M(111.31M)295.5M
Debt Repayment20.32M(3M)(3M)(291.79M)0
Common Stock Issued25.32M19.63M16.76M27.57M43.41M
Common Stock Repurchased(16.57M)(18.2M)(28.47M)(200.28M)(31.03M)
Dividends Paid00000
Other Financing Activities00(275M)(29.64M)0
Financing Cash Flow29.07M(1.57M)(289.71M)(494.14M)12.38M
Effect of Forex Changes00000
Net Change in Cash64.58M(45.07M)165M(166.32M)828.63M
Free Cash Flow72.7M(17.21M)353.31M405.64M480.33M

Alkermes plc

NASDAQ:ALKS

Intrinsic Alpha fair value

Locked

Current Price

$46.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.